AUTHORS
Jimin Park, PhD, Erin Keith Gray2, So Jeong Kim3, Jessica Newton4, Nikhil Nayak5, Sarah Gutch, PhD6, Lindsay Wathen, MSc7, Maegan Capitano, PhD8, Yann Gibert, Ph.D.9, James Ropa, PhD10
AFFILIATIONS
1 Indiana University School of Medicine, Indianapolis, Indiana, United States
2 Indiana University School of Medicine, Indianapolis, Indiana, United States
3 Indiana University School of Medicine, Indianapolis, Indiana, United States
4 Indiana University School of Medicine, Indianapolis, Indiana, United States
5 Indiana University School of Medicine, Indianapolis, Indiana, United States
6 Indiana University School of Medicine, Indianapolis, Indiana, United States
7 Indiana University School of Medicine, Indianapolis, Indiana, United States
8 Indiana University School of Medicine, Indianapolis, Indiana, United States
9 Indiana University School of Medicine, Indianapolis, Indiana, United States
10 Indiana University School of Medicine, Indianapolis, Indiana, United States
ABSTRACT
Background: Hematopoietic stem and progenitor cells (HSPCs) reside in physiologically low-oxygen environments, but the genes that maintain HSPC function under these conditions are not fully understood. Using single-cell transcriptomics, we have identified PRSS2, which encodes the serine protease Trypsin-2, as an oxygen-responsive gene enriched in primitive human HSPCs. Further integration of bulk transcriptomics with functional mouse analyses demonstrated that PRSS2 expression was also associated with increased long-term SCID-repopulating cell (SRC) frequency, suggesting a relationship between PRSS2 expression and HSPC functional potency. Trypsin-2 is primarily produced by the pancreas and is best known as a digestive protease, making its expression and potential function in hematopoietic cells unexpected. PRSS2 expression is also changed in hematologic disease, including reduced expression in aplastic anemia, further suggesting a relationship between PRSS2 and hematopoietic function. Here, we investigated the functional role of PRSS2 in human HSPCs across different oxygen conditions and its contribution to hematopoietic engraftment.
Methods: Human umbilical cord blood CD34+ cells were maintained at 1% or 21% O2 and treated with control or PRSS2-targeting siRNA before transplantation into immunodeficient mice. Human hematopoietic reconstitution was assessed by peripheral blood and bone marrow human CD45+ chimerism and immunophenotypic analysis of bone marrow HSC and progenitor populations. PRSS2 mRNA and protein expression in CD34+ cells cultured at 1%, 5%, 10%, and 21% O2 were assessed by qPCR and quantitative confocal immunofluorescence. As an independent genetic approach, cord blood CD34+ cells were targeted with CRISPR-Cas9 followed by HSPC immunophenotyping, apoptosis analysis, and colony-forming unit (CFU) assays. The effect of active human PRSS2 on hematopoiesis was also evaluated in zebrafish embryos using whole-mount in situ hybridization and qPCR.
Results: PRSS2 mRNA expression, measured by qPCR, was highest at 1% O2 and decreased with increasing oxygen tension. Consistent with these findings, quantitative confocal immunofluorescence demonstrated a corresponding reduction in PRSS2 protein abundance across 1%, 5%, 10%, and 21% O2, supporting oxygen-responsive regulation of PRSS2 in human CD34+ HSPCs. Mining of publicly available patient datasets showed that PRSS2 expression was decreased in CD34+ bone marrow cells from patients with aplastic anemia and partially recovered following immunosuppressive treatment. PRSS2 was also enriched in hematologic malignancies associated with poor clinical outcomes. Following culture at 1% O2, PRSS2 knockdown markedly impaired human hematopoietic reconstitution. At 16 weeks after transplantation, human CD45+ chimerism was significantly decreased in both peripheral blood and bone marrow. Bone marrow analysis also demonstrated a significant reduction in immunophenotypically defined HSCs, while most downstream progenitor populations were less affected. Conversely, ex vivo treatment with recombinant Trypsin-2 increased CD34+ cell expansion, additionally supporting a functional role for PRSS2 in human HSPCs.
Next, we targeted PRSS2 using CRISPR-Cas9 as an independent genetic approach. CRISPR targeting reduced HSC frequency at both 1% and 21% O2 and reduced multipotent progenitor frequency under 1% O2. Under 1% O2, PRSS2 targeting also markedly increased the frequency of apoptotic cells, supporting a role for PRSS2 in HSPC survival under physiologic low oxygen. Consistent with these findings, PRSS2 targeting significantly decreased total colony-forming capacity and multilineage CFU-GEMM output under 1% O2. In an additional in vivo model, treatment of zebrafish embryos with active human PRSS2 significantly increased expression of the erythroid markers hbbe1 and gata1, supporting a role for PRSS2 in hematopoietic regulation.
Conclusions: Our findings identify PRSS2 as an unexpected regulator of human hematopoietic stem and progenitor cell function. PRSS2 is oxygen-responsive, associated with hematologic disease and HSPC potency, and is functionally important for HSPC survival, primitive HSPC maintenance, and hematopoietic engraftment. Independent CRISPR studies and zebrafish analyses moreover support a role for PRSS2 in hematopoietic regulation. Together, these data reveal a previously unrecognized function for the digestive protease Trypsin-2 in hematopoiesis.
DISCLOSURES
Jimin Park, PhD: No relevant conflicts of interest to declare.